Economics of pathogen inactivation technology for platelet concentrates in Japan

International Journal of Hematology

Volumn 80, Issue 4, 2004, Pages 317-324

  Staginnus, Ulf ^a   Corash, Laurence ^b  

^a Premor Associates   (United States)

^b CERUS CORPORATION   (United States)

Author keywords

Cost; Cost effectiveness; Economics; Japan; Pathogen inactivation

Indexed keywords

THROMBOCYTE CONCENTRATE;

APHERESIS; BACTERIUM CONTAMINATION; BLOOD BANK; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION; JAPAN; REVIEW; SAFETY; SCREENING TEST; SEPSIS; THROMBOCYTE TRANSFUSION; TRANSFUSION TRANSMITTED INFECTION; VIRUS INACTIVATION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BACTERIAL INFECTIONS; BLOOD BANKS; BLOOD-BORNE PATHOGENS; COST-BENEFIT ANALYSIS; HUMANS; JAPAN; PLATELET TRANSFUSION; VIRUS DISEASES;

EID: 9444230617     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04131     Document Type: Review

References (44)

1. Mine H, Emura H, Miyamoto M, et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods. 2003;112:145-151.
2. Chieko M, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Takeo J. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001;41:878-884.
3. Cyranoski D. Tainted transfusion leaves Japan scrambling for safer blood tests. Nat Med. 2004;10:217.
4. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83-91.
5. Bureau of Social Welfare and Public Health, Tokyo Metropolitan Government. Securing blood supply. Available at: http://www. fukushihoken.metro.tokyo.jp/soumu/healthcare/providing/blood. htm. Accessed May 24, 2004.
6. Kano S, Kimura M. Trends in malaria cases in Japan. Acta Trop. 2004;89:271-278.
7. Busch MP. Should HBV DNA NAT replace HbsAG and/or anti-HBc screening of blood donors? Transfus Clin Biol. 2004;11:26-32.
8. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol. 1999;107:186-195.
9. Custer B. Economic analysis of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev. 2004;18: 127-143.
10. Satake M. Residual risk of transfusion-transmitted diseases in Japan and pathogen inactivation. Vox Sang. 2002;83(suppl 1):227-279.
11. Barbara J. The rationale for pathogen inactivation treatment of platelet components: introduction. Semin Hematol. 2001;38(suppl 11):1-3.
12. Murokawa H, Minegishi K, Yamanaka R, et al. Status of screening for HCV, HIV and HBV: experience in Japan. Dev Biol. 2002;108: 29-39.
13. Wagner S. Transfusion transmitted bacterial infection: risks, sources and interventions. Vox Sang. 2004;86:157-163.
14. Kawamura A. Transfusion in Japan [editorial]. Transfus Apheresis Sci. 2002;26:113-114.
15. Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Kluter H. Implementation of the Intercept Blood System for platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang. 2004;86:239-245.
16. vanRhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the EuroSPRITE trial. Blood. 2003;101:2426-2433.
17. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25:2464-2486.
18. Omokawa S, Notoya T, Kumagai M, et al. Status of platelet collections and platelet transfusion. Ther Apher. 2001;5:17-21.
19. Abridged Life Tables for Japan: 2002. Available at: www.mhlw.go.jp/ english/database/dh-hw/lifetab02/1.html. Accessed June 29, 2004.
20. Biggerstaff BJ, Pedersen LR. West Nile virus transmission through transfusion during an epidemic in Queens, New York City. Transfusion. 2002;42:1019-1026.
21. Dodd R, Leiby D. Emerging infectious threats to the blood supply. Annu Rev Med. 2004;55:191-207.
22. Matsubayashi K, Nagaoka Y, Sakata H, et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004;44:934-940.
23. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA. 2003;289:959-962.
24. Scimizu YK, Purcell RH, Yoshikura H. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci USA. 1993;90:6037-6041.
25. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583-590.
26. Beckers EAM, teBoekhorst PAW, Vermeij H, vanRhenen DJ. Limitations of routine bacterial screening of platelets with the Bac-Talert system. Vox Sang. 2004;87(suppl 3):6-7.
27. Claeys H, Logghe F, Vandekerchove B, et al. Four-year experience with routine bacterial screening of platelet concentrates. In: Proceedings of the VIII European Congress of the International Society of Blood Transfusion, Istanbul, Turkey, July 5-9, 2003. Amsterdam, The Netherlands: International Society of Blood Transfusion; 2003:56.
28. Hanna HA, Raad I. Blood products: a significant risk factor for long-term catheter-related bloodstream infections in cancer patients. Infect Control Hosp Epidemiol. 2001;22:165-166.
29. Kluter H, Chapuis B, Cazenave JP, et al. Apheresis platelets treated with the Intercept Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets. Vox Sang. 2002;83(suppl 2):110.
30. Osselaer JC, Doyen C, Sonet A, et al. Routine use of platelet components prepared with photochemical treatment (Intercept platelets): impact on clinical outcomes and costs. Blood. In press.
31. Japan Country Profile: Health Care Expenditure by Source. Princeton, NJ: Espicom; 2004:15.
32. Feldman EA, Bayer R. Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster. New York: Oxford University Press; 1999.
33. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104: 1534-1541.
34. Popovsky MA, Chaplin HC Jr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion. 1992;32:589-592.
35. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721-729.
36. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion. 2002;42:980-988.
37. Yey JM, Botteman M, Pashos C, Postma M, Staginnus U. Economics of transfusion. Infus Ther Transfus Med. 2002;29:218-225.
38. Van Hulst M, de Wolf J, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmacoeconomics of blood transfusion safety: review of the available evidence. Vox Sang. 2002;83:146-155.
39. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood. 1998;91: 2180-2188.
40. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209-216.
41. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997; 37:423-435.
42. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44:496-504.
43. Kimura H. Cost of HIV treatment in highly active antiretroviral therapy in Japan [in Japanese]. Nippon Rinsho. 2002;60:813-816.
44. Ishida H, Inoue Y, Wong JB, Okita K. Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapses or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res. 2004;28:125-136.